One study found 279 cancers in 22 families with germline p16 Leiden founder mutation, of which 122 (44%) were melanoma, 25 (21%) were non-melanoma skin cancer, 22 (15%) were pancreatic cancer, 16 (11%) were lung cancer, and 12 (9%) were breast cancer. Here, CDKN2A is linked to cancer.